Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions

Clinical and Vaccine Immunology

Volumn 15, Issue 5, 2008, Pages 872-884

  Eslahpazir, Jobin ^a   Jenabian, Mohammad Ali ^a   Bouhlal, Hicham ^a,f   Hocini, Hakim ^a   Carbonneil, Cédric ^a   Grésenguet, Gérard ^b   Mbopi Kéou, François Xavier ^c   LeGoff, Jérôme ^a,d   Saïdi, Héla ^a   Requena, Mary ^a   Nasreddine, Nadine ^a   Longo, Jean De Dieu ^b   Kaveri, Srinivas V ^a   Bélec, Laurent ^a,d,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hôpital de l'Amitié   (Central African Republic)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DNA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYOSIN; THYROGLOBULIN; TRANSFERRIN; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; VAGINA SECRETION; VIRUS ENTRY; ANTIBODY COMBINING SITE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; UTERINE CERVIX; VAGINA; VIROLOGY;

BINDING SITES, ANTIBODY; CERVIX UTERI; DENDRITIC CELLS; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; MACROPHAGES; RECEPTORS, CCR5; VAGINA;

EID: 46249090660     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00463-07     Document Type: Article

References (53)

1. Avrameas, S., G. Dighiero, P. Lymberi, and B. Guilbert. 1983. Studies on natural antibodies and autoantibodies. Ann. Immunol. (Paris) 134D:103-113.
2. Bard, E., D. Riethmuller, S. Biichle, D. Meillet, J. L. Pretet, C. Mougin, and E. Seilles. 2002. Validation of a high sensitive immunoenzymatic assay to establish the origin of immunoglobulins in female genital secretions. J. Immunoassay Immunochem. 23:145-162.
3. Baumgarth, N., J. W. Tung, and L. A. Herzenberg. 2005. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26:347-362.
4. Belec, L. 2002. Defenses of the female genital tract against infection. J. Gynecol. Obstet. Biol. Reprod (Paris) 31:4S45-4S59. (In French.)
5. Belec, L., T. Dupre, T. Prazuck, C. Tevi-Benissan, J. M. Kanga, O. Pathey, X. S. Lu, and J. Pillot. 1995. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J. Infect. Dis. 172:691-697.
6. Belec, L., D. Meillet, M. Levy, A. Georges, C. Tevi-Benissan, and J. Pillot. 1995. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin. Diagn. Lab. Immunol. 2:57-61.
7. Belec, L., C. Tevi-Benissan, X. S. Lu, T. Prazuck, and J. Pillot. 1995. Local synthesis of IgG antibodies to HIV within the female and male genital tracts during asymptomatic and pre-AIDS stages of HIV infection. AIDS Res. Hum. Retrovir. 11:719-729.
8. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Investig. 102:2072-2081.
9. Binder, C. J., and G. J. Silverman. 2005. Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin. Immunopathol. 26:385-404.
10. Blauvelt, A., H. Asada, M. W. Saville, V. Klaus-Kovtun, D. J. Altman, R. Yarchoan, and S. I. Katz. 1997. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. J. Clin. Investig. 100:2043-2053.
11. Bosmel, M., C. Pastori, D. Tudor, C. Alberti, S. Garcia, D. Ferrari, A. Lazzarin, and L. Lopalco. 2007. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS 21:13-22.
12. Bouhlal, H., H. Hocini, C. Quillent-Gregoire, V. Donkova, S. Rose, A. Amara, R. Longhi, et al. 2001. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J. Immunol. 166:7606-7611.
13. Bouhlal, H., V. Latry, M. Requena, S. Aubry, S. V. Kaveri, M. D. Kazatchkine, L. Belec, and H. Hocini. 2005. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J. Immunol. 174:7202-7209.
14. Bouvet, J. P., H. Hocini, and S. Iscaki. 1992. Secretory component is bound to the paraproteins in sera of IgA and IgM gammopathies. Scand. J. Immunol. 35:79-83.
15. Chomont, N., G. Gresenguet, H. Hocini, P. Becquart, M. Matta, L. Andreoletti, A. Si-Mohamed, M. P. Carreno, et al. 2001. Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal fluid: a prerequisite to assess HIV-specific vaginal immunity and HIV genital shedding. AIDS 15:801-802.
16. Chomont, N., G. Gresenguet, M. Levy, H. Hocini, P. Becquart, M. Matta, J. Tranchot-Diallo, et al. 2001. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin. Diagn. Lab. Immunol. 8:955-958.
17. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
18. Ditzel, H. J., M. M. Rosenkilde, P. Garred, M. Wang, K. Koefoed, C. Pedersen, D. R. Burton, and T. W. Schwartz. 1998. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc. Natl. Acad. Sci. USA 95:5241-5245.
19. Doranz, B. J., J. F. Berson, J. Rucker, and R. W. Doms. 1997. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol. Res. 16:15-28.
20. Duan, B., and L. Morel. 2006. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 5:403-408.
21. Grene, E., L. A. Pinto, A. L. Landay, H. A. Kessler, S. A. Anderson, M. J. Dolan, and G. M. Shearer. 2001. Anti-CCR5 antibodies in sera of HIV-positive individuals. Hum. Immunol. 62:143-145.
22. + Th1 phenotype. J. Immunol. 163:2306-2313.
23. Hocini, H., A. Barra, L. Belec, S. Iscaki, J. L. Preud'homme, J. Pillot, and J. P. Bouvet. 1995. Systemic and secretory humoral immunity in the normal human vaginal tract. Scand. J. Immunol. 42:269-274.
24. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
25. Kaveri, S., N. Prasad, T. Vassilev, V. Hurez, A. Pashov, S. Lacroix-Desmazes, and M. D. Kazatchkine. 1997. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg). Mult. Scler. 3:121-128.
26. Kawamura, T., S. E. Bruse, A. Abraha, M. Sugaya, O. Hartley, R. E. Offord, E. J. Arts, et al. 2004. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J. Virol. 78:7602-7609.
27. Kawamura, T., F. O. Gulden, M. Sugaya, D. T. McNamara, D. L. Borris, M. M. Lederman, J. M. Orenstein, et al. 2003. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. USA 100:8401-8406.
28. Kutteh, W. H., Z. Moldoveanu, and J. Mestecky. 1998. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res. Hum. Retrovir. 14(Suppl. 1):S51-S55.
29. Lederman, M. M., R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak, Jr., et al. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
30. Liu, H., Y. Hwangbo, S. Holte, J. Lee, C. Wang, N. Kaupp, H. Zhu, et al. 2004. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J. Infect. Dis. 190:1055-1058.
31. Lopalco, L., C. Barassi, C. Paolucci, D. Breda, D. Brunelli, M. Nguyen, J. Nouhin, et al. 2005. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J. Gen. Virol. 86:339-348.
32. Manson, J. J., C. Mauri, and M. R. Ehrenstein. 2005. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin. Immunopathol. 26:425-432.
33. Mauck, C. 2005. Overview of why hormones may be an issue. J. Acquir. Immune Defic. Syndr. 38(Suppl. 1):S11-S12.
34. Michael, N. L., G. Chang, L. G. Louie, J. R. Mascola, D. Dondero, D. L. Birx, and H. W. Sheppard. 1997. 1997. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3:338-340.
35. Miller, C. J., and R. J. Shattock. 2003. Target cells in vaginal HIV transmission. Microbes Infect. 5:59-67.
36. Moldoveanu, Z., W. Q. Huang, R. Kulhavy, M. S. Pate, and J. Mestecky. 2005. Human male genital tract secretions: both mucosal and systemic immune compartments contribute to the humoral immunity. J. Immunol. 175:4127-4136.
37. O'Brien, T. R., N. S. Padian, T. Hodge, J. J. Goedert, S. J. O'Brien, and M. Carrington. 1998. CCR-5 genotype and sexual transmission of HIV-1. AIDS 12:444-445.
38. Platt, J. L. 1994. A perspective on xenograft rejection and accommodation. Immunol. Rev. 141:127-149.
39. Prakash, M., S. Patterson, and M. S. Kapembwa. 2005. Hormonal upregulation of CCR5 expression on T lymphocytes as a possible mechanism for increased HIV-1 risk. J. Acquir. Immune Defic. Syndr. 38(Suppl. 1):S14-S16.
40. Pullen, G. R., M. G. Fitzgerald, and C. S. Hosking. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86:83-87.
41. Quillent, C., E. Oberlin, J. Braun, D. Rousset, G. Gonzalez-Canali, P. Metais, L. Montagnier, et al. 1998. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 351:14-18.
42. Saidi, H., J. Eslahpazir, C. Carbonneil, L. Carthagena, M. Requena, N. Nasreddine, and L. Belec. 2006. Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J. Immunol. 177:5540-5554.
43. Unutmaz, D., and D. R. Littman. 1997. Expression pattern of HIV-1 coreceptors on T cells: implications for viral transmission and lymphocyte homing. Proc. Natl. Acad. Sci. USA 94:1615-1618.
44. Vassilev, T. L., and K. V. Veleva. 1996. Natural polyreactive IgA and IgM autoantibodies in human colostrum. Scand. J. Immunol. 44:535-539.
45. Veazey, R. S., P. J. Klasse, T. J. Ketas, J. D. Reeves, M. Piatak, Jr., K. Kunstman, S. E. Kuhmann, et al. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198:1551-1562.
46. Veazey, R. S., P. J. Klasse, S. M. Schader, Q. Hu, T. J. Ketas, M. Lu, P. A. Marx, et al. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102.
47. Veazey, R. S., M. S. Springer, P. A. Marx, J. Dufour, P. J. Klasse, and J. P. Moore. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11:1293-1294.
48. Wang, B., P. Palasanthiran, J. Zeigler, A. Cunningham, and N. K. Saksena. 1997. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 350:742.
49. Williams, S. B., T. P. Flanigan, A. W. Artenstein, T. C. VanCott, D. Smith, K. Mayer, and R. A. Koup. 1999. CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection. J. Infect. Dis. 79:1310-1312.
50. Wolinsky, S. M., R. S. Veazey, K. J. Kunstman, P. J. Klasse, J. Dufour, A. J. Marozsan, M. S. Springer, and J. P. Moore. 2004. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 328:19-29.
51. Wu, L., W. A. Paxton, N. Kassam, N. Ruffing, J. B. Rottman, N. Sullivan, H. Choe, et al. 1997. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185:1681-1691.
52. Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, and H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369-1375.
53. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.